Octane Medical acquires B. Braun’s global orthobiologics business
octane news
Kingston, Ontario, January 2, 2024 – The Octane Medical Group is pleased to announce that the contract development and manufacturing arm of its German subsidiary TETEC AG is now Octane CDMO, an expanded operation with the know-how, years of experience, technology, systems and international network to drive complex, personalized cell therapies from concept to commercialization.
“As the first CDMO to develop and commercialize two in-house ATMPs, Octane CDMO is uniquely positioned to help other ATMP developers safeguard the success of their innovation,” says Timothy Smith, CEO and co-founder of Octane, a global leader in regenerative medicine with the most advanced technologies in cell therapy, spinal implants, medical imaging and bioelectricity. “Our team of seasoned scientists, regulatory experts and manufacturing specialists has a proven track record of bringing cell therapy innovations to market, and to patients around the world.”
Another important differentiator for Octane CDMO is its longstanding expertise in process automation – a strategic advantage that ATMP developers are increasingly seeking. Using third-party technology or Octane’s own Cocoon automated bioreactor, Octane CDMO works with ATMP developers to introduce automation early in their development and commercialization journey. This accelerates model translation, eliminates the need to revalidate manual processes, and leads to economies of scale across development and production.
“We are agile. Drawing on our expertise and tool sets, we will help you find the ideal solution to optimize your process to accelerate and ensure your vision,” says Detlef Schumann, CEO at Octane CDMO. “Our solutions include translating your processes into the GMP environment, manufacturing your clinical specimen, setting up and coordinating clinical trials, obtaining regulatory approvals and helping you to register your ATMP – all delivered through a proven, methodical approach designed to minimize your risk and ensure your success.”
Beyond its scientific, regulatory and production expertise, Octane CDMO offers greater cell product development and manufacturing capacity. ATMP developers who partner with Octane CDMO get access to more than 11,150 square metres (120,000 square feet) of state-of-the-art product development and manufacturing facilities in Canada, Germany and the United States. These facilities are ISO- and GMP-certified, and can run multiple ATMP and medical device projects simultaneously to deliver on a global scale.
The launch of Octane CDMO is the latest milestone in Octane’s global expansion strategy, which includes the acquisition last year of TETEC and Aesculap Biologics LLC in Breinigsville, Pennsylvania, U.S.A. These acquisitions advanced Octane’s goal of bringing new regenerative medicine technologies to patients around the world.
This goal is further amplified with Octane CDMO’s unique abilities and expanded capacity to help ATMP developers around the world bring their innovations to international markets.
“We have lived what it takes to drive complex, personalized cell therapies from concept to profitable commercialization,” says Smith. “We look forward to helping even more ATMP innovators advance with confidence through every stage of their development and commercialization journey.”
Headquartered in Ontario, Canada with locations in the United States and Europe, Octane is a global group of companies with the most advanced bioprocesses, biomaterials and bioreactors for regenerative medicine. We power transformative healthcare with game-changing technologies that we develop and turn into proof-of-concept platforms. These innovations are advanced into production within our market-specific Octane ventures and then launched for commercialization with our global partners. Today, our Octane ventures include Octane Clinical Systems, Octane Orthobiologics, Octane Exo, Octane Biotech and Octane Biotherapeutics (BioTx).
At Octane, our goal is to make regenerative medicine the standard of care. For more information, visit www.octaneco.com.
For media interviews:
Chris Miranda
Business Development, Octane Medical Group of Companies
613-634-6345
Kingston, Ontario, Canada / Melsungen, Germany, June 5th, 2024 – Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun. The acquisition, consisting of the two companies TETEC AG in Germany and Aesculap Biologics, LLC. in the United States, establishes Octane as an international leader in regenerative medicine.
June 5, 2024
Kingston, Ontario, June 2, 2022 – Octane Exo Inc., an Octane Medical Group venture, has achieved a breakthrough in medical implant technology with Octane HyperPEEK, an advanced biocomposite proven to enhance bone regeneration with the goal of enhanced integration and stability.
March 2, 2022
Kingston, Ontario, 15 December 2020 – Octane Medical Group has expanded its state-of-the-art facility in Kingston, Ontario Canada. The 40,000-square-foot building, which Octane purchased in 2011, houses the company's head office and features regulated biolabs for biomaterial and biologics discovery programs including cell therapy research and development, a ...
December 15, 2020
Maine, USA, 18 March 2020 – Octane innovations in tissue engineering, personalized medicine and automated living implant production have earned one of the highest Edison Awards, winning Gold in the Medical / Dental Cellular Research category. The Gold award recognizes AUTOGRAFTA™ living graft technology and the ability to ...
March 18, 2020
